MYALEPTA® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients
Shots:
- First and only therapy approved for LD patients with confirmed or acquired in adults and children ≥2yrs; partial or acquired LD in adults or children ≥12yrs in Europe after being approved by US FDA in 2014
- The approval will prove to be a significant advancement for patients in Europe
- Authorization was on results shown from open –label- single arm study in 48 patients
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
